210 related articles for article (PubMed ID: 31019310)
1. Blue light flexible cystoscopy with hexaminolevulinate in non-muscle-invasive bladder cancer: review of the clinical evidence and consensus statement on optimal use in the USA - update 2018.
Lotan Y; Bivalacqua TJ; Downs T; Huang W; Jones J; Kamat AM; Konety B; Malmström PU; McKiernan J; O'Donnell M; Patel S; Pohar K; Resnick M; Sankin A; Smith A; Steinberg G; Trabulsi E; Woods M; Daneshmand S
Nat Rev Urol; 2019 Jun; 16(6):377-386. PubMed ID: 31019310
[TBL] [Abstract][Full Text] [Related]
2. Clinical and cost effectiveness of hexaminolevulinate-guided blue-light cystoscopy: evidence review and updated expert recommendations.
Witjes JA; Babjuk M; Gontero P; Jacqmin D; Karl A; Kruck S; Mariappan P; Palou Redorta J; Stenzl A; van Velthoven R; Zaak D
Eur Urol; 2014 Nov; 66(5):863-71. PubMed ID: 25001887
[TBL] [Abstract][Full Text] [Related]
3. The use of blue light flexible cystoscopy with hexaminolevulinate & the diagnosis of bladder cancer.
Clinton TN; Lotan Y
Future Oncol; 2018 Nov; 14(27):2805-2810. PubMed ID: 29925279
[TBL] [Abstract][Full Text] [Related]
4. Hexaminolevulinate blue-light cystoscopy in non-muscle-invasive bladder cancer: review of the clinical evidence and consensus statement on appropriate use in the USA.
Daneshmand S; Schuckman AK; Bochner BH; Cookson MS; Downs TM; Gomella LG; Grossman HB; Kamat AM; Konety BR; Lee CT; Pohar KS; Pruthi RS; Resnick MJ; Smith ND; Witjes JA; Schoenberg MP; Steinberg GD
Nat Rev Urol; 2014 Oct; 11(10):589-96. PubMed ID: 25245244
[TBL] [Abstract][Full Text] [Related]
5. Macro and microeconomics of blue light cystoscopy with CYSVIEW® in non-muscle invasive bladder cancer.
Williams SB; Gavaghan MB; Fernandez A; Daneshmand S; Kamat AM
Urol Oncol; 2022 Jan; 40(1):10.e7-10.e12. PubMed ID: 34158205
[TBL] [Abstract][Full Text] [Related]
6. Treatment changes and long-term recurrence rates after hexaminolevulinate (HAL) fluorescence cystoscopy: does it really make a difference in patients with non-muscle-invasive bladder cancer (NMIBC)?
Geavlete B; Multescu R; Georgescu D; Jecu M; Stanescu F; Geavlete P
BJU Int; 2012 Feb; 109(4):549-56. PubMed ID: 21711438
[TBL] [Abstract][Full Text] [Related]
7. Hexaminolevulinate hydrochloride blue-light flexible cystoscopy in the detection and follow-up of nonmuscle-invasive bladder cancer: cost consequences during outpatient surveillance in Sweden.
Dansk V; Malmström PU; Bläckberg M; Malmenäs M
Future Oncol; 2016; 12(8):1025-38. PubMed ID: 26975197
[TBL] [Abstract][Full Text] [Related]
8. Prospective evaluation of blue-light flexible cystoscopy with hexaminolevulinate in non-muscle-invasive bladder cancer.
Lotan Y; Chaplin I; Ahmadi H; Meng X; Roberts S; Ladi-Seyedian S; Bagrodia A; Margulis V; Woldu S; Daneshmand S
BJU Int; 2021 Jan; 127(1):108-113. PubMed ID: 32648957
[TBL] [Abstract][Full Text] [Related]
9. Blue Light Cystoscopy: Indications and Outcomes.
Pohar KS
Curr Urol Rep; 2020 Apr; 21(5):19. PubMed ID: 32248340
[TBL] [Abstract][Full Text] [Related]
10. Patient-reported outcomes of blue-light flexible cystoscopy with hexaminolevulinate in the surveillance of bladder cancer: results from a prospective multicentre study.
Smith AB; Daneshmand S; Patel S; Pohar K; Trabulsi E; Woods M; Downs T; Huang W; Taylor J; Jones J; O'Donnell M; Bivalacqua T; DeCastro J; Steinberg G; Kamat A; Resnick M; Konety B; Schoenberg M; Jones JS; Lotan Y;
BJU Int; 2019 Jan; 123(1):35-41. PubMed ID: 29979488
[TBL] [Abstract][Full Text] [Related]
11. Budget impact of incorporating one instillation of hexaminolevulinate hydrochloride blue-light cytoscopy in transurethral bladder tumour resection for patients with non-muscle-invasive bladder cancer in Sweden.
Rose JB; Armstrong S; Hermann GG; Kjellberg J; Malmström PU
BJU Int; 2016 Jun; 117(6B):E102-13. PubMed ID: 26305667
[TBL] [Abstract][Full Text] [Related]
12. Photodynamic diagnosis of non-muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: a meta-analysis of detection and recurrence based on raw data.
Burger M; Grossman HB; Droller M; Schmidbauer J; Hermann G; Drăgoescu O; Ray E; Fradet Y; Karl A; Burgués JP; Witjes JA; Stenzl A; Jichlinski P; Jocham D
Eur Urol; 2013 Nov; 64(5):846-54. PubMed ID: 23602406
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of hexaminolevulinate fluorescence cystoscopy for the diagnosis of non-muscle-invasive bladder cancer in daily clinical practice: a Spanish multicentre observational study.
Palou J; Hernández C; Solsona E; Abascal R; Burgués JP; Rioja C; Cabrera JA; Gutiérrez C; Rodríguez O; Iborra I; Herranz F; Abascal JM; Conde G; Oliva J
BJU Int; 2015 Jul; 116(1):37-43. PubMed ID: 25496450
[TBL] [Abstract][Full Text] [Related]
14. Clinical and economic impact of blue light cystoscopy in the management of NMIBC at US ambulatory surgical centers: what is the site-of-service disparity?
Shore ND; Gavaghan MB
Urol Oncol; 2023 Apr; 41(4):207.e9-207.e16. PubMed ID: 36564259
[TBL] [Abstract][Full Text] [Related]
15. Hexaminolevulinate blue light cystoscopy (Hal) assisted transurethral resection of the bladder tumour vs white light transurethral resection of the bladder tumour in non-muscle invasive bladder cancer (NMIBC) : a retrospective analysis.
Capece M; Spirito L; La Rocca R; Napolitano L; Buonopane R; Di Meo S; Sodo M; Bracale U; Longo N; Palmieri A; Fusco F; Verze P; Califano G; Crocetto F; Imbimbo C; Mirone V; Imperatore V; Creta M
Arch Ital Urol Androl; 2020 Apr; 92(1):17-20. PubMed ID: 32255316
[TBL] [Abstract][Full Text] [Related]
16. Hexyl aminolevulinate-guided fluorescence cystoscopy in the diagnosis and follow-up of patients with non-muscle-invasive bladder cancer: a critical review of the current literature.
Rink M; Babjuk M; Catto JW; Jichlinski P; Shariat SF; Stenzl A; Stepp H; Zaak D; Witjes JA
Eur Urol; 2013 Oct; 64(4):624-38. PubMed ID: 23906669
[TBL] [Abstract][Full Text] [Related]
17. The cost-effectiveness of blue light cystoscopy in bladder cancer detection: United States projections based on clinical data showing 4.5 years of follow up after a single hexaminolevulinate hydrochloride instillation.
Garfield SS; Gavaghan MB; Armstrong SO; Jones JS
Can J Urol; 2013 Apr; 20(2):6682-9. PubMed ID: 23587507
[TBL] [Abstract][Full Text] [Related]
18. Hexaminolevulinate-guided transurethral resection of non-muscle-invasive bladder cancer does not reduce the recurrence rates after a 2-year follow-up: a prospective randomized trial.
Gkritsios P; Hatzimouratidis K; Kazantzidis S; Dimitriadis G; Ioannidis E; Katsikas V
Int Urol Nephrol; 2014 May; 46(5):927-33. PubMed ID: 24249423
[TBL] [Abstract][Full Text] [Related]
19. [Is a routine second transurethral resection of the bladder still necessary after hexaminolévulinate photodynamic diagnosis-assisted TURBT?].
Doisy L; Walz J; Fakhfakh S; Rybikowski S; Koskas Y; Gravis G; Pignot G
Prog Urol; 2019; 29(6):332-339. PubMed ID: 31104952
[TBL] [Abstract][Full Text] [Related]
20. Hexaminolevulinate-guided fluorescence cystoscopy in the diagnosis and follow-up of patients with non-muscle-invasive bladder cancer: review of the evidence and recommendations.
Witjes JA; Redorta JP; Jacqmin D; Sofras F; Malmström PU; Riedl C; Jocham D; Conti G; Montorsi F; Arentsen HC; Zaak D; Mostafid AH; Babjuk M
Eur Urol; 2010 Apr; 57(4):607-14. PubMed ID: 20116164
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
